EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Clinical Impact of Adjusted Valproic Acid Level in Patients with Hypoalbuminemia: A Single‐Center Cohort Study

Renad Bin Naheet, Khalid Al Sulaiman iD, Khuld Aloufi, Abdullah F Alharthi, Mashael AlFaifi, Lama Nazer, Mohammad Shawaqfeh, Abdulmajeed M Alshehri, Mohammed Abutaleb iD, Abdulaziz Alarifi, Asma A Alshehri, Ahmad H Al-Ani und 10 weitere

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70139 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Renad Bin Naheet und 21 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Valproic Acid, Hypoalbuminemia, Anticonvulsants. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Valproic acid (VPA) is highly protein‐bound, thereby impacting its free fraction and clearance in hypoalbuminemia. There is limited data on VPA use in such patients. Thus, this study evaluates the impact of adjusted VPA concentration (aVPAc) in predicting effectiveness and adverse effects compared to total VPA (tVPA) levels in hypoalbuminemic patients. A retrospective cohort study involved adult patients with seizures or epilepsy between January 1, 2016, and December 31, 2022. The levels of tVPA and aVPA (adjusted for albumin) were compared using receiver operating characteristic curves, and AUC differences were assessed using the DeLong method. Safety endpoints included hepatotoxicity, hyperammonemia, hyponatremia, and thrombocytopenia, while effectiveness endpoints were seizure occurrence, status epilepticus, and the use of additional antiepileptic medications during hospitalization. Of the 1621 screened patients, 71 with hypoalbuminemia received VPA. An aVPAc threshold of 154.19 mg/dL demonstrated higher sensitivity (86%) but lower specificity (47%) for predicting hepatotoxicity compared to a tVPA threshold of 67.53 mg/dL (sensitivity: 71%, specificity: 72%). Although aVPAc yielded a comparable negative predictive value (96% vs 95%), tVPA showed superior positive predictive value (25% vs 18%) and a higher Youden index (0.43 vs 0.33), indicating better overall discriminatory performance; however, these findings did not achieve statistical significance. In contrast, an aVPAc threshold of 188 mg/dL showed a sensitivity of 100% and a specificity of 82% for predicting hyperammonemia, which is superior to the tVPA threshold of 74.32 mg/dL that has a sensitivity of 40% and a specificity of 88%. The aVPAc also achieved a higher Youden index of 0.82 compared to 0.28 for tVPA. Adjusted VPA concentrations showed greater sensitivity than tVPA in predicting hepatotoxicity and hyperammonemia, suggesting potential utility for ruling out these adverse effects in hypoalbuminemic patients. Further research with a larger sample size is needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Valproic AcidHypoalbuminemiaAnticonvulsantsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedEpilepsyCohort StudiesSeizuresChemical and Drug Induced Liver Injury

Stichwörter der Autor:innen

adjusted levelhepatotoxicityhyperammoniahypoalbuminemiathrombocytopeniatotal levelsvalproic acid

Substanzen

Valproic AcidAnticonvulsants

Autor:innen und Institutionen

  • Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
  • Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia.
  • Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society), Riyadh, Saudi Arabia.
  • Department of Clinical Pharmacy, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi City, Riyadh, Saudi Arabia.

ORCID-Profile: Khalid Al Sulaiman, Mohammed Abutaleb, Ohoud Aljuhani

Zitieren

APA

Naheet, R. B., Al Sulaiman, K., Aloufi, K., Alharthi, A. F., AlFaifi, M., Nazer, L., Shawaqfeh, M., Alshehri, A. M., Abutaleb, M., Alarifi, A., Alshehri, A. A., Al-Ani, A. H., Saggaf, O., Vishwakarma, R., Alharbi, M., Alnaser, D., Alrashdi, S., Jaly, A. A., Alenezi, F., …, & Aljuhani, O. (2026). Clinical Impact of Adjusted Valproic Acid Level in Patients with Hypoalbuminemia: A Single‐Center Cohort Study. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70139

Vancouver

Naheet RB, Al Sulaiman K, Aloufi K, Alharthi AF, AlFaifi M, Nazer L, et al. Clinical Impact of Adjusted Valproic Acid Level in Patients with Hypoalbuminemia: A Single‐Center Cohort Study. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70139

BibTeX
@article{Naheet2026,
  author = {Naheet, Renad Bin and Al Sulaiman, Khalid and Aloufi, Khuld and Alharthi, Abdullah F and AlFaifi, Mashael and Nazer, Lama and Shawaqfeh, Mohammad and Alshehri, Abdulmajeed M and Abutaleb, Mohammed and Alarifi, Abdulaziz and Alshehri, Asma A and Al-Ani, Ahmad H and Saggaf, Omar and Vishwakarma, Ramesh and Alharbi, Maryam and Alnaser, Delael and Alrashdi, Saud and Jaly, Abdulaziz A and Alenezi, Farhan and Alkhlewi, Moayad and Alanazi, Abdulelah and Aljuhani, Ohoud},
  title = {Clinical Impact of Adjusted Valproic Acid Level in Patients with Hypoalbuminemia: A Single‐Center Cohort Study},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70139}
}
Kostenlos starten →